GlassScriptPhysician profile
Jordan Duda
NPI 1639875495
$1,943.94
in general payments reported to CMS, 2019-2025
23 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.57 · 2022: $114 · 2023: $1,129 · 2024: $352 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,809.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $316.20 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Regeneron Healthcare Solutions, INC. | $229.86 | 2023-2024 | Dupixent |
| Sanofi-Aventis U.S. LLC | $181.89 | 2023-2025 | |
| Genzyme Corporation | $146.26 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $133.33 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $124.97 | 2023 | Rexulti |
| Lundbeck LLC | $123.30 | 2023 | Vyepti |
| Ucb, INC. | $119.75 | 2023-2024 | Briviact, Nayzilam |
| Lilly USA, LLC | $95.86 | 2022 | |
| Ascendis Pharma Endocrinology INC | $76.63 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.46 | 2024-2025 | Eohilia |
| Novo Nordisk INC | $44.73 | 2023 | Sogroya |
| Abbvie INC. | $41.42 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $40.93 | 2023-2025 | |
| Tandem Diabetes Care, INC. | $39.97 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $39.76 | 2023-2024 | Dysport |
| Medtronic, INC. | $37.10 | 2022-2023 | Minimed 780g |
| Tolmar, INC. | $20.90 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.57 | 2021 | |
| Kyowa Kirin, INC. | $18.56 | 2023 | Crysvita |
| Ironshore Pharmaceuticals INC. | $17.19 | 2023 | Jornay Pm |
| Insulet Corporation | $14.72 | 2023 | Omnipod |
| Biomarin Pharmaceutical INC. | $13.58 | 2023 | Voxzogo 1.2mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Duda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.